ProQR Therapeutics (PRQR) said Wednesday that it will receive an additional $8.1 million research grant from Rett Syndrome Research Trust to support its clinical trials of drug candidate AX-2402.

The grant brings the research trust's total funding in ProQR to $9.1 million, ProQR said.

Rett Syndrome is a rare neurodevelopmental disorder that causes a regression of a child's language and motor skills.